David N Gill - Net Worth and Insider Trading

David N Gill Net Worth

The estimated net worth of David N Gill is at least $2 Million dollars as of 2024-11-29. David N Gill is the CFO of EndoChoice Holdings Inc and owns about 149,204 shares of EndoChoice Holdings Inc (GI) stock worth over $1 Million. David N Gill is the Director of Evolus Inc and owns about 33,964 shares of Evolus Inc (EOLS) stock worth over $468,703. David N Gill is also the Director of Strongbridge Biopharma PLC and owns about 74,896 shares of Strongbridge Biopharma PLC (SBBP) stock worth over $149,792. Besides these, David N Gill also holds Ocugen Inc (OCGN) , Melinta Therapeutics Inc (MLNTQ) , Y-mAbs Therapeutics Inc (YMAB) . Details can be seen in David N Gill's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David N Gill has not made any transactions after 2024-05-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of David N Gill

To

David N Gill Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David N Gill owns 9 companies in total, including Strongbridge Biopharma PLC (SBBP) , Y-mAbs Therapeutics Inc (YMAB) , and Evolus Inc (EOLS) among others .

Click here to see the complete history of David N Gill’s form 4 insider trades.

Insider Ownership Summary of David N Gill

Ticker Comapny Transaction Date Type of Owner
SBBP Strongbridge Biopharma PLC 2020-09-24 director
YMAB Y-mAbs Therapeutics Inc 2021-01-19 director
EOLS Evolus Inc 2024-05-14 director
LIMIT LIMIT 2019-11-22 director
LIMIT LIMIT 2019-06-11 director
LIMIT LIMIT 2017-08-16 director
LIMIT LIMIT 2016-11-22 President and CFO
LIMIT LIMIT 2006-10-18 director
LIMIT LIMIT 2006-05-10 SVP & CFO

David N Gill Latest Holdings Summary

David N Gill currently owns a total of 6 stocks. Among these stocks, David N Gill owns 149,204 shares of EndoChoice Holdings Inc (GI) as of March 10, 2016, with a value of $1 Million and a weighting of 65.86%. David N Gill owns 33,964 shares of Evolus Inc (EOLS) as of May 14, 2024, with a value of $468,703 and a weighting of 25.86%. David N Gill also owns 74,896 shares of Strongbridge Biopharma PLC (SBBP) as of September 24, 2020, with a value of $149,792 and a weighting of 8.26%. The other 3 stocks Ocugen Inc (OCGN) , Melinta Therapeutics Inc (MLNTQ) , Y-mAbs Therapeutics Inc (YMAB) have a combined weighting of 0.02% among all his current holdings.

Latest Holdings of David N Gill

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
GI EndoChoice Holdings Inc 2016-03-10 149,204 8.00 1,193,632
EOLS Evolus Inc 2024-05-14 33,964 13.80 468,703
SBBP Strongbridge Biopharma PLC 2020-09-24 74,896 2.00 149,792
OCGN Ocugen Inc 2017-08-16 233 0.97 226
MLNTQ Melinta Therapeutics Inc 2018-05-25 1,200 0.11 132
YMAB Y-mAbs Therapeutics Inc 2021-01-19 0 11.88 0

Holding Weightings of David N Gill


David N Gill Form 4 Trading Tracker

According to the SEC Form 4 filings, David N Gill has made a total of 0 transactions in EndoChoice Holdings Inc (GI) over the past 5 years. The most-recent trade in EndoChoice Holdings Inc is the acquisition of 2,000 shares on March 10, 2016, which cost David N Gill around $9,400.

According to the SEC Form 4 filings, David N Gill has made a total of 2 transactions in Evolus Inc (EOLS) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Evolus Inc is the sale of 10,361 shares on May 14, 2024, which brought David N Gill around $130,963.

According to the SEC Form 4 filings, David N Gill has made a total of 1 transactions in Strongbridge Biopharma PLC (SBBP) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Strongbridge Biopharma PLC is the acquisition of 8,000 shares on September 24, 2020, which cost David N Gill around $17,040.

More details on David N Gill's insider transactions can be found in the Insider Trading History of David N Gill table.

Insider Trading History of David N Gill

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David N Gill Trading Performance

GuruFocus tracks the stock performance after each of David N Gill's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David N Gill is 10.7%. GuruFocus also compares David N Gill's trading performance to market benchmark return within the same time period. The performance of stocks bought by David N Gill within 3 months outperforms 5 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how David N Gill's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of David N Gill

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
4 out of 8 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 6.2 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 4.33 LIMIT LIMIT LIMIT LIMIT LIMIT

David N Gill Ownership Network

Ownership Network List of David N Gill

No Data

Ownership Network Relation of David N Gill

Insider Network Chart

David N Gill Owned Company Details

What does Strongbridge Biopharma PLC do?

Who are the key executives at Strongbridge Biopharma PLC?

David N Gill is the director of Strongbridge Biopharma PLC. Other key executives at Strongbridge Biopharma PLC include 10 percent owner Cdk Associates, L.l.c. , 10 percent owner Caxton Corp , and 10 percent owner Bruce Kovner .

Strongbridge Biopharma PLC (SBBP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Strongbridge Biopharma PLC (SBBP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Strongbridge Biopharma PLC (SBBP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Strongbridge Biopharma PLC (SBBP)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Strongbridge Biopharma PLC Insider Transactions

No Available Data

David N Gill Mailing Address

Above is the net worth, insider trading, and ownership report for David N Gill. You might contact David N Gill via mailing address: C/o Nxstage Medical Inc. (nxtm), 439 South Union Street, 5th Floor, Lawrence Ma 01843.

Discussions on David N Gill

No discussions yet.